DOCSLIB.ORG

Erythema Annulare Centrifugum ▪ Erythema Gyratum Repens ▪ Exfoliative Erythroderma Urticaria ▪ COMMON: 15% All Americans

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Erythema Annulare Centrifugum ▪ Erythema Gyratum Repens ▪ Exfoliative Erythroderma Urticaria ▪ COMMON: 15% All Americans Cutaneous Signs of Internal Malignancy Ted Rosen, MD Professor of Dermatology Baylor College of Medicine Disclosure/Conflict of Interest ▪ No relevant disclosures ▪ No conflicts of interest Objectives ▪ Recognize common disorders associated with internal malignancy ▪ Manage cutaneous disorders in the context of associated internal malignancy ▪ Differentiate cutaneous signs of leukemia and lymphoma ▪ Understand spidemiology of cutaneous metastases Cutaneous Signs of Internal Malignancy ▪ General physical examination ▪ Pallor (anemia) ▪ Jaundice (hepatic or cholestatic disease) ▪ Fixed erythema or flushing (carcinoid) ▪ Alopecia (diffuse metastatic disease) ▪ Itching (excoriations) Anemia: Conjunctival pallor and Pale skin Jaundice 1-12% of hepatocellular, biliary tree or pancreatic cancer PRESENT with jaundice, but up to 40-60% eventually develop it World J Gastroenterol 2003;9:385-91 For comparison CAN YOU TELL JAUNDICE FROM NORMAL SKIN? JAUNDICE Alopecia Neoplastica Most common report w/ breast CA Lung, cervix, desmoplastic mm Hair loss w/ underlying induration Biopsy = dermis effaced by tumor Ann Dermatol 26:624, 2014 South Med J 102:385, 2009 Int J Dermatol 46:188, 2007 Acta Derm Venereol 87:93, 2007 J Eur Acad Derm Venereol 18:708, 2004 Gastric Adenocarcinoma: Alopecia Ann Dermatol 2014; 26: 624–627 Pruritus: Excoriation ▪ Overall risk internal malignancy presenting as itch LOW. OR =1.14 ▪ CTCL, Hodgkin’s & NHL, Polycythemia vera ▪ Biliary tree carcinoma Eur J Pain 20:19-23, 2016 Br J Dermatol 171:839-46, 2014 J Am Acad Dermatol 70:651-8, 2014 Non-specific (Paraneoplastic) Specific (Metastatic Disease) Paraneoplastic Signs “Curth’s Postulates” ▪ Concurrent onset (temporal proximity) ▪ Parallel course ▪ Uniform site or type of neoplasm ▪ Statistical association ▪ Genetic linkage (syndromal) Curth HO. Skin lesions and internal carcinoma. In: Andrade R, Gumport SL, Popkin GL, Rees TD, eds. Cancer of the Skin. Philadelphia: WB Saunders; 1976:1308-1309 Paraneoplastic Dermatoses ▪ Acanthosis nigricans ▪ Ichthyosis (acquired) ▪ Bazex syndrome ▪ Paget’s disease of the breast ▪ Clubbing of nails ▪ Paget’s disease ▪ Dermatomyositis (extramammary) ▪ Erythema gyratum (and ▪ Paraneoplastic pemphigus other figurate erythemas) ▪ Porphyria cutanea tarda (PCT) ▪ Exfoliative erythroderma ▪ Pyoderma gangrenosum ▪ Glucagonoma ▪ Scleromyxedema ▪ Hyperpigmentation ▪ Sign of Leser-Trélat ▪ Hypertrichosis lanuginosa ▪ Sweet’s Syndrome Acanthosis Nigricans ▪ Velvety pigmentation (ASx) ▪ Neck or axilla typical ▪ Neoplastic (~20%): Rapid onset ▪ Adenocarcinoma (90%) GI & GU; MOST COMMONLY GASTRIC ▪ 60% concurrent, 20% before and 20% after cancer dx ▪ Also seen in obesity and insulin- resistant diabetes and in purely hereditary form Arch Dermatol 66:80, 1952 Cancer 15:364, 1962 Indian Online Derm J 5:239, 2014 Acanthosis Nigricans IGF = Insulin-like growth factor Adapted from: Dermatol Online J. 14(9):2, 2008 IGF = Insulin-like growth factor In malignancy TGF-α Adapted from: Dermatol Online J. 14(9):2, 2008 Acanthosis Nigricans ▪ In children, typically not due to malignancy (obesity) ▪ Ethnic predilection (children): Native Americans, Blacks: High Hispanics: Moderate Caucasians: Low Illustrative Case ▪ 45 year-old female ▪ CC: Rash under arms ▪ Overweight ▪ Not diabetic, not hypertensive, no dyslipidemia ▪ No meds; good health ▪ No systemic or localizing signs or symptoms ▪ Negative Family history ▪ + Mammogram: ASx ductal carcinoma found Dermatomyositis ▪ Heliotrope (30-60%) ▪ Positive auto-antibodies ▪ Gottron’s papules (70%) ▪ Nondestructive ▪ Erythema + scale elbow/knee arthralgia/arthritis ▪ Proximal muscle weakness ▪ Fever ▪ Elevated CPK ▪ Elevated ESR ▪ Elevated aldolase ▪ Calcinosis cutis ▪ Muscle pain ▪ Pathologic biopsy = ▪ Abnormal EMG skeletal muscle myositis Dermatomyositis ▪ Malignancy in adult DM, not juvenile DM ▪ 7-30% DM assoc w/ malignancy Clin Dermatol 24:363, 2006; G Ital Dermatol Venereol 149:525-37, 2014 ▪ Relative risk of malignancy is 6.5x greater if DM present, than if not Curr Rheum Rep 4415, 2002 ▪ “Real” risk increases with: ↑age, male gender, dysphagia Br J Dermatol. 2013;169:838-4 ▪ Most often: Ovarian, Breast, Lung, Gastric ▪ Lymphoma also rarely reported ▪ May relate to cross-reacting auto-antibodies Curr Opin Rheumatol 18:620, 2006 Dermatomyositis Dermatomyositis: Malignancy Illustrative Case ▪ 61 year-old ▪ Acute onset weakness ▪ Concurrent rash on torso, knees, elbows ▪ Elevated CPK and ESR ▪ Work up: abnormal chest x-ray ▪ Biopsy: bronchogenic carcinoma Dermatomyositis Workup ▪ EXCLUDE: Ichthyosis vulgaris and Xerosis - IV starts early in life - Xerosis starts late in life; itchy ▪ Medication Hx, Examine for muscle weakness ▪ Examine for adenopathy ▪ Biopsy skin; Screening labs: CBC, SMAC, Fasting glucose, HIV, TSH, PTH, ANA, CPK, CXR, age-sex appropriate cancer screen (age >40) ▪ CT scans, HTLV titers, SPEP ▪ J Am Acad Dermatol 55:647, 2006 Dermatomyositis Workup: Auto-Antibodies ▪ anti-TIF1γ, NXP2, SAE, MDA5, Jo-1, Mi2, PL-7, PL-12, MJ ▪ 96% specific and 67% sensitive ▪ Helps rule-out genetic or toxic myopathy ▪ Anti-TIF1γ & NXP-2 especially associated w/ malignancy ▪ Anti-TIF1γ + (50-75% cancer) and NXP-2+ (13.6% cancer) USA: Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e172 Europe: Autoimmun Rev. 2014;13:1211-9 Japan: Curr Opin Rheumatol. 2016;28:636-44 Reactive Patterns ▪ Urticaria (hives) ▪ Erythema multiforme ▪ Erythema annulare centrifugum ▪ Erythema gyratum repens ▪ Exfoliative erythroderma Urticaria ▪ COMMON: 15% all Americans ▪ “Acute” Food/drug (usually obvious) ▪ “Chronic” Daily, > 6 weeks ▪ NO cause found in 80-90% ▪ Lymphoma (B-cell) Leukemia (CLL) Thyroid carcinoma ▪ Hepatitis (HBV, HCV) ▪ RA, SLE, JRA ▪ Abscess, sinusitis, otitis, Trichomonas, Candida, Parasites J Investig Allergol Clin Immunol 17:192, 2007 Ann Dermatol 24:453, 2012 Urticaria: Valid Association? ▪ In one large prospective study (1155 patients) with chronic urticaria, no association with any type of visceral or hematological malignancy was found. ▪ Br J Dermatol 123:453–6, 1990 Erythema Gyratum Repens ▪ Concentric erythema, trailing edge scales ▪ Mild pruritus ▪ “Wood Grain” morphology ▪ Trunk primary site ▪ Rash usually precedes cancer diagnosis (80%) ▪ Variable sites/types of malignancy, but lung is the most common ▪ Rare but reliable sign of cancer Am J Med Sci 321:302, 2001 JAAD 54:745, 2006 ▪ 85-100% association BMJ Case Rep. 2016; Mar 7; pii: bcr2016214665 69 year-old male 3 month itchy rash 100 pack-yr smoker w/ symptomatic COPD Denies weight loss, hemoptysis, dyspnea or cough Dx: Erythema gyratum CT scan + lesion RUL T4N2M0 bronchogenic CA Eur J Dermatol 18:197, 2008 69 year-old male 3 month itchy rash 100 pack-yr smoker w/ symptomatic COPD Denies weight loss, hemoptysis, dyspnea or cough Dx: Erythema gyratum CT scan + lesion RUL T4N2M0 bronchogenic CA Eur J Dermatol 18:197, 2008 Erythema Annulare Centrifugum ▪ Annular, arcuate and polycyclic ▪ Erythema, scale (min) ▪ DDx: Tinea, SCLE ▪ Internal cancer: Lung most common ▪ Myeloma; Leukemia (various) ▪ Tuberculosis ▪ Dental abscess ▪ Drug & Food allergy EAC: CLL Derm Online J 12(6):11, 2006 ▪ 58 year-old female ▪ 3 month hx serpiginous erythema with scale ▪ W/U revealed stromal smooth muscle cancer of the stomach: resected ▪ Rash resolved ▪ 3 months later: rash resumed and then nodules appeared ▪ Bx nodule = original cancer ▪ Patient refused further Rx and died 1 year later of metz Exfoliative Erythroderma ▪ Widespread red and then scaly skin ▪ ITCHY ▪ Complications Dehydration Protein loss High output CHF Local infection Septicemia Nail shedding Rosen T, et al Am Fam Phys 59:625, 1999 Exfoliative Erythroderma Pre-existing skin 50% disease (eg Psoriasis) Drug reaction 10% Malignancy 10% (may be occult) Idiopathic 30% Dermatol Clin 18:405, 2000 Exfoliative Erythroderma CTCL Hodgkins Illustrative Case ▪ 63 year-old with 2 mo history of red, scaly, itchy skin ▪ No prior skin disorder, no meds, good health, nl labs ▪ Skin biopsy nonspecific ▪ Workup unproductive ▪ Repeated evaluations: 6 mo Colonic adenoCA discovered ▪ Resection: erythroderma resolved Rosen T, Chappell R, Drucker C. Exfoliative dermatitis: presenting sign of visceral internal malignancy. South Med J. 72:652-3, 1979 Exfoliative Erythroderma: Due to Rx ▪ All EGRF-inhibitors ▪ Chlorambucil ▪ Denileukin diftitox ▪ Interferon ▪ Thalidomide ▪ Pentostatin ▪ Cisplatin ▪ Therapeutic arsenic ▪ Erythropoietin Glucagonoma Syndrome ▪ “Necrolytic migratory erythema” ▪ Intertrigo-like: raw and scaling groin; face, extremities ( pigment) ▪ Glossitis, cheilitis ▪ Weight loss ▪ Hyperglycemia ▪ Personality changes ▪ Islet-cell pancreatic tumor Eur J Endocrinol 151:531, 2004 Hepatobiliary Pancreat Dis Int 3:473, 2004 J Eur Acad Dermatol Venereol 30:2016-22, 2016 Glucagonoma Eur J Endocrinol 151:531-7, 2004 Hypertrichosis Lanuginosa ▪ “Malignant down” ▪ 66 total cases as of 2007 ▪ 10:1 = Female:Male ▪ Age 40-70 ▪ Abundant fine hair growth on face; rarely elsewhere ▪ Lung, colon and prostate primary malignancies ▪ Different from hirsutism: terminal hair growth all over ▪ Actas Dermosifiliogr 96:459-61, 2005 ▪ Br J Dermatol 157:1087, 2007 J Cutan Med Surg 19:507-10, 2015 Hypertrichosis Lanuginosa Hypertrichosis Lanuginosa Ichthyosis (Acquired) ▪ Rhomboidal scales ▪ Extremities ▪ Resembles very severe dry skin Hypothyroidism, ESRD Sarcoidosis, SLE, DM, HIV+ (25%), Diabetes (50%), TB, Hansen’s, Medications Cancer: Hodgkin’s (70%), KS, Non-Hodgkin’s Lymphomas, T- cell lymphoma, myeloma, Rare: CA ovary, breast, lung, Cx Am J Clin
Load more

Recommended publications
  • Neonatal Dermatology Review
    NEONATAL Advanced Desert DERMATOLOGY Dermatology Jennifer Peterson Kevin Svancara Jonathan Bellew DISCLOSURES No relevant financial relationships to disclose Off-label use of acitretin in ichthyoses will be discussed PHYSIOLOGIC Vernix caseosa . Creamy biofilm . Present at birth . Opsonizing, antibacterial, antifungal, antiparasitic activity Cutis marmorata . Reticular, blanchable vascular mottling on extremities > trunk/face . Response to cold . Disappears on re-warming . Associations (if persistent) . Down syndrome . Trisomy 18 . Cornelia de Lange syndrome PHYSIOLOGIC Milia . Hard palate – Bohn’s nodules . Oral mucosa – Epstein pearls . Associations . Bazex-Dupre-Christol syndrome (XLD) . BCCs, follicular atrophoderma, hypohidrosis, hypotrichosis . Rombo syndrome . BCCs, vermiculate atrophoderma, trichoepitheliomas . Oro-facial-digital syndrome (type 1, XLD) . Basal cell nevus (Gorlin) syndrome . Brooke-Spiegler syndrome . Pachyonychia congenita type II (Jackson-Lawler) . Atrichia with papular lesions . Down syndrome . Secondary . Porphyria cutanea tarda . Epidermolysis bullosa TRANSIENT, NON-INFECTIOUS Transient neonatal pustular melanosis . Birth . Pustules hyperpigmented macules with collarette of scale . Resolve within 4 weeks . Neutrophils Erythema toxicum neonatorum . Full term . 24-48 hours . Erythematous macules, papules, pustules, wheals . Eosinophils Neonatal acne (neonatal cephalic pustulosis) . First 30 days . Malassezia globosa & sympoidalis overgrowth TRANSIENT, NON-INFECTIOUS Miliaria . First weeks . Eccrine
    [Show full text]
  • Skin Manifestation of SARS-Cov-2: the Italian Experience
    Journal of Clinical Medicine Article Skin Manifestation of SARS-CoV-2: The Italian Experience Gerardo Cazzato 1 , Caterina Foti 2, Anna Colagrande 1, Antonietta Cimmino 1, Sara Scarcella 1, Gerolamo Cicco 1, Sara Sablone 3, Francesca Arezzo 4, Paolo Romita 2, Teresa Lettini 1 , Leonardo Resta 1 and Giuseppe Ingravallo 1,* 1 Section of Pathology, University of Bari ‘Aldo Moro’, 70121 Bari, Italy; [email protected] (G.C.); [email protected] (A.C.); [email protected] (A.C.); [email protected] (S.S.); [email protected] (G.C.); [email protected] (T.L.); [email protected] (L.R.) 2 Section of Dermatology and Venereology, University of Bari ‘Aldo Moro’, 70121 Bari, Italy; [email protected] (C.F.); [email protected] (P.R.) 3 Section of Forensic Medicine, University of Bari ‘Aldo Moro’, 70121 Bari, Italy; [email protected] 4 Section of Gynecologic and Obstetrics Clinic, University of Bari ‘Aldo Moro’, 70121 Bari, Italy; [email protected] * Correspondence: [email protected] Abstract: At the end of December 2019, a new coronavirus denominated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was identified in Wuhan, Hubei province, China. Less than three months later, the World Health Organization (WHO) declared coronavirus disease-19 (COVID-19) to be a global pandemic. Growing numbers of clinical, histopathological, and molecular findings were subsequently reported, among which a particular interest in skin manifestations during the course of the disease was evinced. Today, about one year after the development of the first major infectious foci in Italy, various large case series of patients with COVID-19-related skin Citation: Cazzato, G.; Foti, C.; manifestations have focused on skin specimens.
    [Show full text]
  • Shingles (Herpes Zoster) Hives (Urticaria) Psoriasis
    Shingles (Herpes Zoster) Shingles starts with burning, tingling, or very sensitive skin. A rash of raised dots develops into painful blisters that last about two weeks. Shingles often occurs on the trunk and buttocks, but can appear anywhere. Most people recover, but pain, numbness, and itching linger for many -- and may last for months, years, or the rest of their lives. Treatment with antiviral drugs, steroids, antidepressants, and topical agents can help. Hives (Urticaria) A common allergic reaction that looks like welts, hives are often itchy, and sometimes stinging or burning. Hives vary in size and may join together to form larger areas. They may appear anywhere and last minutes or days. Medications, foods, food additives, temperature extremes, and infections like strep throat are some causes of hives. Antihistamines can provide relief. Psoriasis A non-contagious rash of thick red plaques covered with white or silvery scales, psoriasis usually affects the scalp, elbows, knees, and lower back. The rash can heal and recur throughout life. The cause of psoriasis is unknown, but the immune system triggers new skin cells to develop too quickly. Treatments include medications applied to the skin, light therapy, and medications taken by mouth, injection or infusion. Eczema Eczema describes several non-contagious conditions where skin is inflamed, red, dry, and itchy. Stress, irritants (like soaps), allergens, and climate can trigger flare-ups though they're not eczema's exact cause, which is unknown. In adults, eczema often occurs on the elbows and hands, and in "bending" areas, such as inside the elbows. Treatments include topical or oral medications and shots.
    [Show full text]
  • BETA Betamethasone Valerate Cream 0.1% W/W Betamethasone Valerate Ointment 0.1% W/W
    NEW ZEALAND CONSUMER MEDICINE INFORMATION BETA Betamethasone valerate cream 0.1% w/w Betamethasone valerate ointment 0.1% w/w discoid lupus Some of the symptoms of an What is in this leaflet erythematosus (recurring allergic reaction may include: scaly rash) shortness of breath; wheezing or This leaflet answers some common prickly heat skin reaction difficulty breathing; swelling of the questions about BETA Cream and insect bite reactions face, lips, tongue or other parts of Ointment. prurigo nodularis (an itching the body; rash, itching or hives on and thickening of the skin the skin. It does not contain all the available with lumps or nodules) information. It does not take the contact sensitivity reactions Do not use BETA Cream or place of talking to your doctor or an additional treatment for Ointment to treat any of the pharmacist. an intense widespread following skin problems as it reddening and inflammation could make them worse: All medicines have risks and of the skin, infected skin (unless the benefits. Your doctor has weighed when milder topical corticosteroids infection is being treated the risks of you using BETA Cream cannot treat the skin condition with an anti-infective or Ointment against the benefits effectively. medicine at the same time) they expect it will have for you. acne BETA Cream is usually used to rosacea (a facial skin If you have any concerns about treat skin conditions on moist condition where the nose, taking this medicine, ask your surfaces; BETA Ointment is usually cheeks, chin, forehead or doctor or pharmacist. used to treat skin conditions on dry, entire face are unusually scaly skin.
    [Show full text]
  • Causes and Features of Erythroderma 1 1 2 1 Grace FL Tan, MBBS, Yan Ling Kong, MBBS, Andy SL Tan, MBBS, MPH, Hong Liang Tey, MBBS, MRCP(UK), FAMS
    391 Erythroderma: Causes and Features—Grace FL Tan et al Original Article Causes and Features of Erythroderma 1 1 2 1 Grace FL Tan, MBBS, Yan Ling Kong, MBBS, Andy SL Tan, MBBS, MPH, Hong Liang Tey, MBBS, MRCP(UK), FAMS Abstract Introduction: Erythroderma is a generalised infl ammatory reaction of the skin secondary to a variety of causes. This retrospective study aims to characterise the features of erythroderma and identify the associated causes of this condition in our population. Materials and Methods: We reviewed the clinical, laboratory, histological and other disease-specifi c investigations of 225 inpatients and outpatients with erythroderma over a 7.5-year period between January 2005 and June 2012. Results: The most common causative factors were underlying dermatoses (68.9%), idiopathic causes (14.2%), drug reactions (10.7%), and malignancies (4.0%). When drugs and underlying dermatoses were excluded, malignancy-associated cases constituted 19.6% of the cases. Fifty-fi ve percent of malignancies were solid-organ malignancies, which is much higher than those previously reported (0.0% to 25%). Endogenous eczema was the most common dermatoses (69.0%), while traditional medications (20.8%) and anti-tuberculous medications (16.7%) were commonly implicated drugs. In patients with cutaneous T-cell lymphoma (CTCL), skin biopsy was suggestive or diagnostic in all cases. A total of 52.4% of patients with drug-related erythroderma had eosinophilia on skin biopsy. Electrolyte abnormalities and renal impairment were seen in 26.2% and 16.9% of patients respectively. Relapse rate at 1-year was 17.8%, with no associated mortality.
    [Show full text]
  • Drug Eruptions.Pdf
    Drug eruptions & reactions What are drug eruptions? Drug reactions are unwanted and unexpected reactions occurring in the skin (and sometimes other organ systems) that may result from taking a medication for the prevention, diagnosis or treatment of a medical problem. They may appear after the correct use of the medication or drug. It may also appear due to overdose (wrong dose is taken), following accumulation of drugs in the body over time, or by interactions with other medications being taken or used by the person. Drug eruptions could be caused by an allergy or hypersensitivity to the drug, by a direct toxic effect of the drug or medication on the skin, or by other mechanisms. Drug eruptions vary in severity – from a minor nuisance to a more severe problem – and may even cause death. Drug eruptions occur in up to 15% of courses of drug prescribed by medical or natural therapy practitioners. What causes drug eruptions? Drug eruptions are caused by medications which are prescribed by your doctor, purchased over-the- counter or purchased as compounded herbal/naturopathic medicines. Drugs taken orally, injected, delivered by patch application, rubbed onto the skin (e.g. creams, ointments and lotions) can all cause reactions. The potential to develop an adverse reaction to a drug is influenced by the age, gender and genetic makeup of the person; the nature of the condition being treated; and the possible interactions with other medications being taken. Some classes of drugs are known to cause drug eruptions more commonly than others. What do drug eruptions look like in the skin? The appearance of drug eruptions varies depending on the mechanism of the drug reaction.
    [Show full text]
  • Successful Treatment of Refractory Pityriasis Rubra Pilaris With
    Letters Discussion | The results of this study reveal important differ- OBSERVATION ences in the microbiota of HS lesions in obese vs nonobese pa- tients. Gut flora alterations are seen in obese patients,4,5 and Successful Treatment of Refractory Pityriasis HS has been associated with obesity. It is possible that altered Rubra Pilaris With Secukinumab gut or skin flora could have a pathogenic role in HS. Pityriasis rubra pilaris (PRP) is a rare inflammatory skin dis- Some of the limitations of the present study include the order of unknown cause. It is characterized by follicular use of retrospective data and the lack of a control group con- hyperkeratosis, scaly erythematous plaques, palmoplantar sisting of patients with no history of HS. Although these cul- keratoderma, and frequent progression to generalized tures were obtained from purulence extruding from HS le- erythroderma.1 Six types of PRP are distinguished, with type sions, the bacterial culture results could represent skin or gut 1 being the most common form in adults. Disease manage- flora contamination. Information about the specific ana- ment of PRP is challenging for lack of specific guidelines. Topi- tomic locations of HS cultures was not available. Because only cal emollients, corticosteroids, and salicylic acid alone or com- the first recorded culture of each patient was analyzed, it is un- bined with systemic retinoids, methotrexate, and tumor known if the culture results would change with time and fur- necrosis factor (TNF) inhibitors are considered to be most ther antibiotic therapy. The use of data obtained from swab- helpful.2,3 Unfortunately, PRP often resists conventional treat- based cultures may also represent a potential limitation because ment.
    [Show full text]
  • Cutaneous Manifestations of Systemic Disease
    Cutaneous Manifestations of Systemic Disease Dr. Lloyd J. Cleaver D.O. FAOCD FAAD Northeast Regional Medical Center A.T.Still University/KCOM Assistant Vice President/Professor ACOI Board Review Disclosure I have no financial relationships to disclose I will not discuss off label use and/or investigational use in my presentation I do not have direct knowledge of AOBIM questions I have been granted approvial by the AOA to do this board review Dermatology on the AOBIM ”1-4%” of exam is Dermatology Table of Test Specifications is unavailable Review Syllabus for Internal Medicine Large amount of information Cutaneous Multisystem Cutaneous Connective Tissue Conditions Connective Tissue Diease Discoid Lupus Erythematosus Subacute Cutaneous LE Systemic Lupus Erythematosus Scleroderma CREST Syndrome Dermatomyositis Lupus Erythematosus Spectrum from cutaneous to severe systemic involvement Discoid LE (DLE) / Chronic Cutaneous Subacute Cutaneous LE (SCLE) Systemic LE (SLE) Cutaneous findings common in all forms Related to autoimmunity Discoid LE (Chronic Cutaneous LE) Primarily cutaneous Scaly, erythematous, atrophic plaques with sharp margins, telangiectasias and follicular plugging Possible elevated ESR, anemia or leukopenia Progression to SLE only 1-2% Heals with scarring, atrophy and dyspigmentation 5% ANA positive Discoid LE (Chronic Cutaneous LE) Scaly, atrophic plaques with defined margins Discoid LE (Chronic Cutaneous LE) Scaly, erythematous plaques with scarring, atrophy, dyspigmentation DISCOID LUPUS Subacute Cutaneous
    [Show full text]
  • Itching to Know More About Eczema and Ectodermal Dysplasia
    ITCHING TO KNOW MORE ABOUT ECZEMA AND ECTODERMAL DYSPLASIA Eczema, sometimes called dermatitis, is inflammation of the skin that can lead to an itchy rash. There are many different types of eczema, but the most common kind of eczema is atopic dermatitis. When people refer to eczema, they are typically referring to atopic dermatitis. This condition affects up to 20% of people worldwide, particularly infants and children. Individuals with ectodermal dysplasia, especially hypohidrotic ectodermal dysplasia (HED), are affected even more commonly than the general population with up to 50% having atopic dermatitis. The exact cause of atopic seasonal allergies, asthma or and on the neck and face. dermatitis is unknown. But, eczema. As the rash becomes more there are many factors that established, the dry skin may make a person prone to this Rarely, atopic dermatitis may be become thickened, leathery, and type of rash. We know the related to food sensitivity, but sometimes darker in coloration main issue in eczema is that this is actually quite rare as food due to repetitive rubbing and the skin barrier that holds in allergies typically cause hives scratching. moisture and protects us is not and not eczema. In the majority functioning optimally. This is of cases, no allergic triggers When the rash improves, the case even in those without can be found. Therefore, allergy the skin may appear lighter ectodermal dysplasia, but the testing in most cases is not for some time, especially in poorly developed sweat and necessary or helpful in treating a the summer months but this oil glands likely affect the skin person’s eczema.
    [Show full text]
  • Casanova J.M, Puig T, Rubio M. Hypertrichosis of the Eyelashes in 59. Acquired Immunodeficiency Syndrome Arch. Dermatol 1987, 12
    Dermatosis Paraneoplásicas 59. Casanova J.M, Puig T, Rubio M. Hypertrichosis of the eyelashes in 80. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Thernau TM. acquired immunodeficiency syndrome Arch. Dermatol 1987, 123: POEMS syndrome: definitions and long - term outcome. Blood 1559-601 2003;101: 2496-2506 60. Tegner.E, Tegner.H Acquired curly hair , a new paraneoplastic 81. Larson D, Grepp PR, Witzig TE, Basu R, Suare G, Fonseca R, symptom? Acta Dermo Venereol 1998 Jul; 78 (4): 302 Lust J, Gertz MA. POEMS syndrome: definitions and long-term 61. Pecora AL, Landsman L, Imgrund SP, Lambert C. Acrokanatosis outcome. Blood 2003;101(7) 2496-2506 Paraneoplastica (Bazex Syndrome). Arch Dermatol 1983; 119: 82. Reeder MJ, Wetter DA, Li X, Davis MDP. Incidence of 820-826 dermatomyositis and clinically amyopathic dermatomyositis. 62. Bazex A. Paraneoplastiche Akrokeratose. Der Hautarzt 1979 30: A population-Based study in Olensted County. Arch Dermatol 119-123 2010;146(1): 26-30 63. Rio Ramirez MT, Casado Lopez ME, Peiron Puyal MJ, Peñas 83. Wakata N, Kurihara T, Saito E, Kinoshita M. Polimyositis and Herrero JM. Adenocarcinoma de pulmon y síndrome de Bazex dermatomyositis associated with malignancy: a 30 years (acroqueratosis paraneoplásica). Arch Bronconeumol 2007;Jan 43 retrospective study. Int J Dermatol 2002;41: 729-734 (1) 46-8 84. Nishigori K, Yamamoto T, Yokozeki H. Vesicobullous 64. Niitani A, Matsuura H, Kuyama M, Fujimoto W. Paraneoplastic dermatomyositis: Report of three cases DOJ April 2009, 15(4) dermatosis suspected of being Bazex syndrome in a woman with 85. Kurokawa M, Koketsu H, Oda Y, Nagamine H, Toyama T, Hashimoto breast mama.
    [Show full text]
  • Drug-Induced Papuloerythroderma: Analysis of T-Cell Populations and a Literature Review
    Acta Derm Venereol 2009; 89: 618–622 CLINICAL REPORT Drug-induced Papuloerythroderma: Analysis of T-cell Populations and a Literature Review Kazunari SUGita1, Kenji KABASHIMA1,2, Motonobu NAKAMURA1 and Yoshiki TOKURA1 Department of Dermatology, 1University of Occupational and Environmental Health, and 2Kyoto University Graduate School of Medicine, Kyoto, Japan Papuloerythroderma of Ofuji is characterized by coale­ of solid papules, which typically spare the skin folds, scent solid papules that spare the skin folds. Although cu­ presenting the so-called “deck-chair” sign. Although its taneous lymphomas and internal malignancies are known association with cutaneous T-cell lymphoma as well as associated conditions, the causative agents are unclear in visceral carcinomas has been documented in a consi- most cases. A number of recent reports have documente d derable number of cases, the aetiology of the condition that drugs can induce papuloerythroderma. We review­ is unclear in the vast majority of patients (2). However, ed the reported cases and our own cases of drug­induc­ recent reports have indicated that drugs are causative ed papulo erythroderma, together with our data from agents for papuloerythroderma (3, 4) and have suggested lympho cyte transformation tests and T­cell subsets of that drug-reactive T-helper (Th) 2 cells play an important peri pheral blood. All of the 9 patients were male, and the role in the pathogenesis (5). causative drugs were various. Provocation tests were po­ The populations of circulating T cells can be skewed sitive in all 6 patients examined. Whereas drug patch tests upon occurrence of T-cell-mediated drug eruptions (6, were negative in all 5 cases tested, the patients’ peripheral 7).
    [Show full text]
  • RIPE for the PICKING Experts Profile the Future of Biologic Treatments
    RIPE FOR THE PICKING Experts profile the future of biologic treatments 22 DERMATOLOGY WORLD // September 2015 www.aad.org/dw BY VICTORIA HOUGHTON, ASSISTANT MANAGING EDITOR John Harris, MD, PhD, assistant professor of medicine at the University of Massachusetts in the division of dermatology — like many dermatologists — has watched the impressive evolution of treatments for psoriasis over the last decade with anticipation. “We initially had very broad immunosuppressants that were somewhat effective in some patients, but they also had significant side effects,” Dr. Harris said. However, “The onset of biologics and other targeted therapies has been incredible. They’ve revolutionized treatment for psoriasis.” However, while physicians are enthusiastic about the progress of these treatments for psoriasis, there is also hope that interest in developing these innovative therapies is increasingly shifting to other skin conditions. “Pharmaceutical companies have to start looking elsewhere, given how good current psoriasis therapies are,” Dr. Harris said. “The real room for growth is in other diseases.” As psoriasis has paved the way for an interest in developing biologic and other targeted treatments in skin conditions, physicians are anticipating a promising future for these treatments in the following conditions: Atopic dermatitis Hidradenitis suppurativa Chronic urticaria Vitiligo Dermatomyositis >> Alopecia areata DERMATOLOGY WORLD // September 2015 23 RIPE FOR THE PICKING Atopic dermatitis 133; 6:1626-34). The study showed that by blocking the According to Lawrence Eichenfield, MD, professor of immune pathways with CsA, the molecular abnormalities dermatology and pediatrics at the University of California, with AD skin barrier genes, such as filaggrin and loricrin, San Diego and chief of pediatric and adolescent dermatology normalized.
    [Show full text]